TSE:4502Pharmaceuticals
Takeda Pharmaceutical TSE 4502 Valuation Check After Positive Zasocitinib Phase 3 Psoriasis Data
Takeda Pharmaceutical (TSE:4502) is back in focus after releasing new Phase 3 data for its investigational TYK2 inhibitor zasocitinib in moderate to severe plaque psoriasis, paired with plans for future regulatory filings.
See our latest analysis for Takeda Pharmaceutical.
The zasocitinib data appear to have arrived during a strong run for the shares, with a 90-day share price return of 19.92% and a 1-year total shareholder return of 33.75% suggesting momentum has been building over both...